Objective-ATP binding cassette transporter G1 (ABCG1) facilitates cholesterol efflux from macrophages to mature high-density lipoprotein particles. Whether genetic variation in ABCG1 affects risk of atherosclerosis in humans remains to be determined. Methods and Results-We resequenced the core promoter and coding regions of ABCG1 in 380 individuals from the general population. Next, we genotyped 10 237 individuals from the Copenhagen City Heart Study for the identified variants and determined the effect on lipid and lipoprotein levels and on risk of myocardial infarction (MI) and ischemic heart disease (IHD). g.Ϫ376CϾT, g.-311TϾA, and Ser630Leu predicted risk of MI in the Copenhagen City Heart Study, with hazard ratios of 2.2 (95% confidence interval: 1.2-4.3), 1.7 (1.0 -2.9), and 7.5 (1.9 -30), respectively. These results were confirmed for g.Ϫ376CϾT in a case-control study comprising 4983 independently ascertained IHD cases and 7489 controls. Expression levels of ABCG1 mRNA were decreased by approximately 40% in g.Ϫ376CϾT heterozygotes versus noncarriers (probability values: 0.005-0.009). Finally, in vitro specificity protein 1 (Sp1) bound specifically to a putative Sp1 binding site at position Ϫ382 to Ϫ373 in the ABCG1 promoter, and the presence of the Ϫ376 T allele reduced binding and transactivation of the promoter by Sp1. Conclusion-This is the first report of a functional variant in ABCG1 that associates with increased risk of MI and IHD in the general population. (Arterioscler Thromb Vasc Biol. 2012;32:506-515.)
M acrophages are key elements in the development of atherosclerosis. 1, 2 Because these cells are unable to limit their lipid uptake, they rely on efficient cholesterol efflux transporters to prevent lipid accumulation. 3, 4 ATP binding cassette transporter G1 (ABCG1) is a transmembrane cholesterol transporter that effluxes cellular cholesterol from macrophages by delivering cholesterol to mature high-density lipoprotein (HDL) particles. 5 As discussed by Westerterp et al, it is controversial whether whole-body Abcg1 knockout mice have increased atherosclerosis. 6 In Abcg1 Ϫ/Ϫ /Apolipoprotein E-deficient mice fed a wild-type diet, atherosclerosis was decreased, 7 whereas in Abcg1 Ϫ/Ϫ mice fed an atherogenic diet, atherosclerosis was increased. 8 Whether genetic variation in ABCG1 affects risk of disease in humans remains to be determined.
Because ABCG1 has been reported to be a key transporter of cholesterol from lipid-poor to mature HDL particles based on in vitro studies, we reasoned that genetic variation in ABCG1 might affect levels of HDL cholesterol in plasma.
Therefore, to increase the likelihood of identifying genetic variants with effect on HDL cholesterol, 9, 10 we resequenced the core promoter, coding regions, and consensus splice sites of ABCG1 in individuals in the general population with the lowest 2% (nϭ190) and highest 2% (nϭ190) HDL cholesterol levels for age and sex. Next, we genotyped 10 237 individuals from the general population, the Copenhagen City Heart Study (CCHS), for the variants identified, and determined the association with plasma levels of HDL cholesterol and other lipids and lipoproteins, and the ability of these variants to predict risk of myocardial infarction (MI) and ischemic heart disease (IHD) with 34 years of follow-up. Finally, genetic variants associated with risk of MI or IHD in the CCHS were validated in a case-control study comprising 4983 independently ascertained IHD cases, of which 2921 had an MI, and 7489 healthy controls from the CCHS.
One variant, Ϫ376CϾT in genomic DNA (g.Ϫ376CϾT), 11 located in a putative specificity protein 1 (Sp1) binding site, consistently associated with an increased risk of MI and IHD in both studies. We therefore measured expression levels of ABCG1 mRNA in g.Ϫ376CϾT heterozygotes versus noncarriers and complemented the human studies with extensive functional studies of the ABCG1 promoter in vitro and in vivo.
Methods

Human Studies
Subjects
Studies were approved by institutional review boards and Danish ethical committees and were conducted according to the Declaration of Helsinki. Written informed consent was obtained from participants. All participants were white and of Danish descent.
The CCHS
The CCHS is a prospective cardiovascular study of the Danish general population initiated in 1976 to 1978 with follow-up examinations in 1981 to 1983, 1991 to 1994, and 2001 to 2003. Individuals were randomly selected based on the national Danish Civil Registration System to reflect the adult Danish general population, aged 20 to 80 years or above. We genotyped 10 237 individuals for the genetic variants identified by resequencing the core promoter of ABCG1 (nucleotides Ϫ1632 to ϩ123 relative to ϩ1 in ATG, NT_030188; Supplemental Figure I, available online at http://atvb.ahajournals.org), the coding regions corresponding to the main transcript, 12, 13 and all consensus splice sites in individuals from the CCHS with the 2% lowest (nϭ190) and 2% highest (nϭ190) HDL cholesterol levels for age and gender (Supplemental Table I ). Follow-up started in 1976 and ended at the date of death, occurrence of event, emigration, or on August 2010 (last update of the complete national Danish registries), whichever came first. Follow-up time was 34 years (243 000 person-years) and was 100% complete, ie, none were lost to follow-up.
Information on diagnoses of IHD (World Health Organization, International Classification of Diseases, 8th edition: codes 410 -414; 10th edition: codes I20 -I25) was collected and verified by reviewing all hospital admissions and diagnoses entered in the national Danish Patient Registry, all causes of death entered in the national Danish Causes of Death Registry, and medical records from hospitals and general practitioners. IHD was fatal or nonfatal MI or characteristic symptoms of stable angina pectoris, including revascularization procedures. 14 A diagnosis of MI followed the changing definitions over time. After year 2000, the diagnosis was based on either of the following: (1) typical rise and fall of biochemical markers of myocardial necrosis (troponin or creatine kinase muscle brain function [CK-MB]) with at least one of the following: ischemic symptoms, development of pathological Q waves on the ECG, ECG changes indicative of ischemia, or coronary artery intervention; or (2) pathological findings of an acute, healed, or healing MI, 15 with later changes as indicated. 16 A total of 2076 participants had IHD, of whom 985 had MI.
The Copenhagen Ischemic Heart Disease Study
To validate whether ABCG1 variants associated with risk of MI and IHD in an independent study, a case-control study was conducted, the Copenhagen Ischemic Heart Disease Study (CIHDS). The cases were 4983 consecutive patients from the greater Copenhagen area referred for coronary angiography to Copenhagen University Hospital, during the period 1991 through 2010. These patients had documented IHD based on characteristic symptoms of angina pectoris, 14 plus at least one of the following: stenosis/atherosclerosis on coronary angiography, a previous MI, or a positive bicycle exercise test. The diagnosis of MI was established with the same criteria as described above. Of the 4983 cases with IHD, 2921 had MI. Cases with IHD were compared with 7489 controls without ischemic cardiovascular events (IHD or ischemic cerebrovascular disease) from the CCHS.
mRNA Expression Analyses of ABCG1 g.؊376C>T
Total RNA was isolated from the buffy coat of 34 g.Ϫ376CϾT heterozygotes and 68 noncarriers, matched 1:2 by age and sex, followed by first-strand cDNA synthesis and quantitative real-time polymerase chain reaction analysis using the relative standard curve method and GAPDH as the endogenous control. For details, please see the Supplemental Methods.
Biochemical Analyses, Covariates, Sequencing, Genotyping, and Statistical Analyses
Please see the Supplemental Methods.
In Vitro and In Vivo Cell Studies of ABCG1 g.؊376C>T
Binding of Sp1 to the ABCG1 promoter and Sp1-mediated transactivation were explored with DNA affinity precipitation assays, competition assays with biotinylated DNA probes, chromatin immunoprecipitation assays in HEK293T cells, and transactivation assays in Drosophila S2 cells as detailed in the Supplemental Methods.
Results
We resequenced the core promoter (nucleotide Ϫ1632 to nucleotide ϩ123; Supplemental Figure I ), the coding regions corresponding to the main transcript, 12, 13 and all consensus splice sites of ABCG1 in 380 individuals with extreme levels of HDL cholesterol. Next, we genotyped 10 237 individuals from the general population, the CCHS, for all promoter variants (except insertions/deletions), nonsynonymous, synonymous, and splice-site variants identified (for a complete list of all 19 variants genotyped, see Supplemental Table I ). Three variants, g.-311TϾA, g.Ϫ376CϾT, and Ser630Leu, which predicted risk of MI and IHD in the CCHS, were validated in a second study, including 4983 independently ascertained IHD cases. One variant, g.Ϫ376CϾT (minor allele frequencyϭ0.2%, no TT homozygotes identified), located in a putative Sp1 binding site, consistently associated with an increased risk of MI and IHD in both studies. We therefore measured expression levels of ABCG1 mRNA in g.Ϫ376CϾT heterozygotes versus noncarriers and complemented the human studies with extensive functional studies of the ABCG1 promoter in vitro and in vivo.
Characteristics of participants in the CCHS and the CIHDS by disease status are shown in the Table.
Genetic Variation in ABCG1 and HDL Cholesterol
Genetic variants identified by resequencing 190 individuals with the 2% lowest and 190 individuals with the 2% highest HDL cholesterol levels for age and sex in the CCHS are shown in Supplemental Table I , as are the allele frequencies in the extreme HDL cholesterol groups, and in the entire CCHS. Pairwise linkage disequilibria for variants with allele frequencies Ն0.002 are shown in Supplemental Figure II. Two of 16 variants (3 singletons excluded), g.-1082CϾT and G327ϾT, were associated with modest reductions in HDL cholesterol of 7% and 3%, respectively, versus noncarriers (Pϭ0.01 and Pϭ0.03; Figure 1 ). However, none of these predicted risk of MI or IHD. No other associations between ABCG1 variants and levels of lipids, lipoproteins, and apolipoproteins were observed.
Risk of MI and IHD
Multifactorially adjusted hazard ratios for MI were 2.2 (95% confidence interval: 1.2-4.3), 1.7 (1.0 -2.9), and 7.5 (1.9 -30) in heterozygotes for g.Ϫ376CϾT, g.-311TϾA, and Ser630Leu, respectively, versus noncarriers ( Figure  1 ). The corresponding hazard ratios for IHD were 1.9 (1.2-3.2), 1.3 (0.8 -1.9), and 6.3 (2.0 -20), respectively. The cumulative incidence of MI and IHD as a function of age was increased in g.Ϫ376CϾT heterozygotes versus noncarriers (Figure 2A and 2B; log-rank probability values: 0.002 and 0.001, respectively). At the age of 80 years, the cumulative incidence of IHD was Ͼ50% in g.Ϫ376CϾT heterozygotes and 25% in noncarriers. Longevity, ie, the proportion surviving as a function of age, was decreased in g.Ϫ376CϾT heterozygotes versus noncarriers ( Figure 2C ; Pϭ0.05).
To validate these findings, we tested for associations between g.Ϫ376CϾT, g.-311TϾA, and Ser630Leu and risk of MI and IHD in the CIHDS, comprising 4983 independently ascertained IHD cases, of which 2921 had experienced an MI, and 7489 controls without ischemic cardiovascular disease from the CCHS. For g.Ϫ376CϾT heterozygotes versus noncarriers, multifactorially adjusted odds ratios were 1.9 (0.8 -4.2) for MI and 2.4 (1.2-4.6) for IHD ( Figure 3 , left panels), confirming the results from the CCHS. To maximize power, we combined cases from CCHS and CIHDS and compared them with 7489 controls without ischemic cardiovascular disease from the CCHS. Results for g.Ϫ376CϾT were similar (Figure 3 
mRNA Expression Levels in g.؊376C>T Heterozygotes Versus Noncarriers
The mRNA expression of ABCG1 was decreased by 36% in 34 g.Ϫ376CϾT heterozygotes versus 68 noncarriers, matched 1:2 by age and gender (Figure 4 , Pϭ0.005). These results were reproduced in an independent experiment (Pϭ0.009; data not shown), using the buffy coat from the same people but isolated at different times. The cell composition of the buffy coat did not differ between g.Ϫ376CϾT heterozygotes and noncarriers for neutrophils, eosinophils, monocytes, basophils, lymphocytes, or other leukocytes (probability values: 0.24 -0.97). *Cases in the Copenhagen Ischemic Heart Disease Study were compared with 7489 healthy controls from the Copenhagen City Heart Study, free of IHD or ischemic cerebrovascular disease. The risk factors diabetes, smoking, and antihypertensive therapy were dichotomized and defined as diabetes (self-reported disease, use of insulin, use of oral hypoglycemic drugs, or nonfasting plasma glucose Ͼ11 mmol/L), smokers (current smoker), and antihypertensive therapy (use of antihypertensive drugs).
Table. Characteristics of Participants in the Copenhagen City Heart Study and in the Copenhagen Ischemic Heart Disease Study by Ischemic Heart Disease Status
†PϽ0.001. ‡Individuals with less than 4 h/wk of light physical activity at leisure time. 
Binding of Sp1 to the ABCG1 Promoter, and Sp1-Mediated Transactivation
Primers and probes used in DNA affinity precipitation, chromatin immunoprecipitation, and transactivation assays are shown in Supplemental Tables II and III. Positions of putative Sp1 sites and other putative nuclear factor binding sites in the ABCG1 promoter are shown in Supplemental Figure I . The ABCG1 core promoter contains 3 putative Sp1 binding sites at positions Ϫ566, Ϫ382 (GCCCAGCCCC; position Ϫ376 underlined), and Ϫ184, respectively 12 (Supplemental Figure I) . To determine whether the g.Ϫ376CϾT variant was biologically functional, we performed in vitro and in vivo cell studies. First, we used DNA affinity precipitation assays to establish that the g.Ϫ376CϾT variant was located in a functional Sp1 site. A DNA probe corresponding to the Ϫ391/Ϫ361 ABCG1 promoter bearing the C allele (Ϫ376C) bound Sp1 with high affinity ( Figure 5A, lane 3) . In contrast, Sp1 could not bind to a similar DNA probe bearing the T allele at position Ϫ376 (Ϫ376T, Figure 5A, lane 4) . As a positive control, we used a DNA probe corresponding to the Ϫ118/ϩ205 ABCA1 promoter shown previously to harbor a functional Sp1 binding site ( Figure 5A , lane 5). 17 As a negative control, we used an unrelated probe corresponding to the region around the TATA box of the human ABCA1 promoter ( Figure 5A, lane 6) . Thus, these experiments showed that Sp1 bound specifically to the putative Sp1 site described by Langmann 12 at position -382 (GCCCAGCCCC; position Ϫ376 underlined; Supplemental Figure I) in vitro, and that the presence of the g.Ϫ376T allele markedly reduced binding. Competition assays further substantiated that Sp1 bound to the Ϫ391/Ϫ361 region of the ABCG1 promoter. As shown in Figure 5B (lanes 3-6) , binding of Sp1 to the ABCG1 probe was competed out by increasing amounts of an oligonucleotide corresponding to the Ϫ63/Ϫ45 region of the human p21 promoter (p21 [Sp1wt]) bearing a well characterized Sp1 target site, 18 whereas a mutated human p21 promoter (p21 [Sp1mut]) was unable to displace Sp1 from the ABCG1 probe ( Figure 5B, lanes 7-9) .
The binding of endogenous Sp1 to the human ABCG1 promoter in vivo was established by chromatin immunoprecipitation assays in HEK293T cells. As shown in Figure  5C , Sp1 was found to be constitutively associated with chromatin fragments corresponding to the proximal ABCG1 promoter (Ϫ487/Ϫ144) which includes 2 Sp1 sites at position Ϫ382 and Ϫ184, respectively (3.2-fold enriched binding compared with control), whereas binding of Sp1 to these sites was reduced by 44% in the presence of mithramycin A, a well established Sp1 inhibitor 19 (a representative original image is shown in Supplemental Figure III ). Finally, transactivation assays in Drosophila S2 cells that lack endogenous Sp1 or related activities, 20 showed that the human Ϫ1080/ϩ14 ABCG1 core promoter bearing the g.Ϫ376C allele (plus 2 additional putative Sp1 sites at positions Ϫ566 and Ϫ184; shown in Supplemental Figure I and IV) , was strongly transactivated by Sp1 (103.5-fold) ( Figure 5D, left panel) . Mutating the Sp1 site centered at nucleotide Ϫ376C to Ϫ376T decreased the Sp1-mediated transactivation of the ABCG1 promoter by 64% ( Figure 5D, right panel) . The promoter retained partial activity, probably because of binding of Sp1 to the 2 other sites, which were still intact. In contrast, Sp2 and Sp3 did not stimulate the ABCG1 promoter to significant Figure 5D ). Thus, these experiments showed that Sp1 also bound to the human ABCG1 promoter in vivo ( Figure 5C ) and was strongly transactivated specifically by Sp1 in cells that lack endogenous Sp1 ( Figure 5D , left panel) and that this transactivation was severely reduced by mutating the Sp1 site at Ϫ376C to Ϫ376T ( Figure 5D , right panel).
Discussion
The principal findings of this study are as follows: (1) ABCG1, g.Ϫ376CϾT, located in a putative Sp1 binding site, predicted an increased risk of MI and IHD and reduced longevity in the general population without affecting levels of HDL cholesterol or other lipids or lipoproteins. (2) The increased risk of MI and IHD was validated in a large case-control study. (3) Expression levels of ABCG1 mRNA were reduced in g.Ϫ376CϾT heterozygotes compared with noncarriers. (4) Extensive functional studies in vitro and in vivo showed that g.Ϫ376CϾT was indeed located in a functional Sp1 binding site and that the presence of the g.Ϫ376 T allele substantially reduced binding and transactivation of the promoter by Sp1. This is the first report of a functional genetic variant in ABCG1, which predicts an increased risk of MI and IHD in humans.
Based on data from in vitro studies, ABCG1 has been suggested to have a critical role in mediating cholesterol efflux to mature HDL particles, thus preventing cellular lipid accumulation, [21] [22] [23] and has consequently been suggested to protect against atherosclerosis. Recently, 3 groups reported transplantation studies of Abcg1-deficient (Abcg1 Ϫ/Ϫ ) bone marrow into Ldl receptor-deficient mice with apparently contrasting effects on atherosclerotic lesion formation. 24 -26 These discrepancies were suggested to be due to differences in dietary composition. 27 Studies of whole-body deficiency of Abcg1 have also lead to conflicting results. In Abcg1 Ϫ/Ϫ /Apolipoprotein E-deficient mice fed a wild-type diet, atherosclerosis was decreased, 7 whereas in Abcg1 Ϫ/Ϫ mice on a C57BL/6 background without Ldl receptor or Apolipoprotein E deficiency, atherosclerosis was increased. 8 In the latter model, although the cholesterol levels were lower, the diet included 0.5% cholate, which results in increased inflammatory responses in certain tissues and very small atherosclerotic lesions in normal mice. Thus, this area of investigation is at present highly controversial.
A recent case-only study of 109 Japanese men with coronary artery disease reported increased severity of coronary artery disease associated with a common polymorphism, rs5601744 TϾG, in the ABCG1 promoter. 28 This polymorphism is located 19 720 base pairs upstream of the ATG start site of the main transcript. In the CCHS, the frequency of the minor allele (G allele) was 0.21 and did not tag the minor allele (T allele) of g.Ϫ376CϾT (r 2 ϭ0.008). The rs5601744 SNP also did not associate with risk of MI or IHD in the CCHS (hazard ratio for IHD: 0.9 [95% CI: 0.9 -1.0]) and therefore could not explain our findings.
A likely explanation for the observed association of g.Ϫ376CϾT with risk of MI, IHD, and longevity in the present study is the finding that this site is indeed regulated by Sp1. The reduced binding and transactivation of the human core promoter carrying the mutant T allele suggests that the mutation associates with a reduction in ABCG1 expression. In accordance with this, we demonstrated a reduction in levels of ABCG1 mRNA in g.Ϫ376CϾT heterozygotes versus noncarriers. Because ABCG1 is a transmembrane cholesterol transporter and may have a role in effluxing cellular cholesterol from macrophages to mature HDL particles, a reduction in ABCG1 expression would result in accumulation of lipids in macrophages in the vascular wall and in the lungs as observed in knockout mice, 8 and clinically in an increased risk of atherosclerosis and thus MI and IHD as observed in the present studies in humans. However, because the most important contribution to HDL biogenesis and thus to plasma levels of HDL cholesterol is hepatic and intestinal ABCA1, 29, 30 genetic variation in ABCG1 affecting risk of ischemic vascular disease would not be expected to contribute substantially to variation in levels of HDL cholesterol in plasma as also observed in the present study and in previous studies of Abcg1-deficient mice.
However, as mentioned above, the evidence to support that ABCG1 is a key transporter of cholesterol from lipid-poor to mature HDL is based mainly on in vitro studies of macrophages. In addition to macrophages, ABCG1 is expressed in other cell types, such as endothelial cells and pancreatic ␤ cells, and deficiency of ABCG1 in these cells may therefore also contribute to atherogenesis. 6, 31, 32 Consequently, the reduced levels of ABCG1 mRNA in g.Ϫ376CϾT heterozygotes observed in the present study, may lead to reduced endothelial nitric oxide synthase activity and increased atherogenesis, as shown in Abcg1 Ϫ/Ϫ /Ldlr Ϫ/Ϫ mice compared with Ldlr Ϫ/Ϫ mice, when transplanted with wild-type bone marrow to specifically investigate the role of vascular ABCG1. 6 Reduced endothelial nitric oxide synthase activity may in turn lead to increased monocyte-endothelial cell interactions and vascular inflammation, as shown in aortic endothelial cells isolated from ABCG1 knockout mice. 32 Finally, impaired insulin secretion has been observed in pancreatic ␤ cells from Abcg1 knockout mice both in vivo and in vitro, without an effect on cellular cholesterol content or efflux. 31 All these effects may potentially contribute to the lipid and lipoprotein independent effects of g.Ϫ376CϾT on risk of MI and IHD observed in the present study and may suggest that ABCG1 is not a key transporter of cholesterol from lipid-poor to mature HDL in vivo.
Neither metaanalyses of all genome-wide association studies of blood lipid traits 33 nor metaanalyses of susceptibility to coronary artery disease 34 have identified ABCG1 as a candidate gene. However, to be captured in these studies, the variant either must be on the array or must be tagged by common single-nucleotide polymorphisms on the array. The latter is unlikely for rare variants. 35 Neither the rare g.Ϫ376CϾT (minor allele frequency: 0.2%), which associated with MI and IHD, nor the relatively rare variants, g.-1082CϾT and G237 (minor allele frequency: 0.6% and 4.0%), which associated with modest decreases in HDL cholesterol but not with risk of MI or IHD in the present study, were present on or tagged by other singlenucleotide polymorphisms on these commercial arrays. 33, 34 This may explain why ABCG1 was not identified as a candidate gene for coronary heart disease or HDL cholesterol levels in these genome-wide association studies.
In a recent study, Edmondson et al used a custom-made array designed to include 66 HDL cholesterol gene loci selected on the basis of HDL biology, candidate genes, and results from previous genome-wide association studies. 36 In this study, rs914189 in ABCG1 (intervening sequence 11-293CϾG; minor allele frequency 0.21) was associated with HDL cholesterol levels; however, risk of coronary heart disease was not determined. The 2 rare variants associated with HDL cholesterol in our study were not present on this array.
In conclusion, we have identified a functional genetic variant in the ABCG1 promoter that associates with an increased risk of MI and IHD in the general population. This is the first report to demonstrate a role for genetic variation in ABCG1 in risk of ischemic vascular disease in the general population. Ϫ376CϾT heterozygotes vs noncarriers. Real-time quantitative polymerase chain reaction was performed in duplicate in 2 independent experiments, using the buffy coat from the same people but isolated at different times. Results from one of 2 experiments are shown, but they were reproducible in the second experiment. mRNA levels were expressed as percentage of noncarriers using the relative standard curve method and GAPDH as the endogenous control. g.Ϫ376CϾT heterozygotes were matched 1:2 with noncarriers by age and sex. The mean C T values for ATP binding cassette transporter G1 (ABCG1) and GAPDH in noncarriers were 30.2 and 26.6, respectively, and corresponding values in g.Ϫ376 heterozygotes were 29.5 and 25.7. A relative ABCG1 mRNA concentration was obtained by division of the ABCG1 concentration by the GAPDH concentration. 6) . B, Competition assays with biotinylated DNA probes corresponding to the Ϫ391/Ϫ361 region of the human ABCG1 promoter bearing the Ϫ376 C allele (lanes 3-9) in the presence of an increasing molar excess (0.5, 1.0, and 1.5 mol/L) of nonbiotinylated double-stranded probes corresponding to the wild-type (wt) (lanes 4 -6), or mutated (lanes 7-9) Ϫ63/Ϫ45 region of the human p21 promoter. 18 The Sp1 promoter binding assays in A and B were performed twice using different extracts and the results were identical. WB, Western blot. C, Chromatin immunoprecipitation assays in HEK293T cells treated with 0.2 mol/L mithramycin A for 24 hours or untreated cells using an antibody for Sp1. Polymerase chain reaction primers corresponding to the Ϫ487/Ϫ144 region of the ABCG1 promoter (including 2 Sp1 sites at positions Ϫ382/Ϫ373 and Ϫ184/Ϫ176). Mithramycin A is a well-established inhibitor of Sp1 binding to DNA. The chromatin immunoprecipitation assays were performed 2 times, and the polymerase chain reactions of each experiment were replicated twice. *PϽ0.05. D, Transactivation assays in Drosophila S2 cells using the Ϫ1080/ϩ14 ABCG1 promoter, including putative Sp1 sites at positions Ϫ566/Ϫ558, Ϫ382/Ϫ373, and Ϫ184/Ϫ176 (left panel, Ϫ376 C allele; right panel, Ϫ376 T allele) (1 g each) along with Drosophila expression vectors for Sp1, Sp2, or Sp3 (5 ng each). The hsp-lacZ plasmid (0.5 g) was used for normalization. Relative luciferase activity is shown. The values for the transactivation assays are the average of 4 transfections.
